# Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)

Study · id `cardio:ct-nct07083765` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07083765](<https://clinicaltrials.gov/study/NCT07083765>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07083765

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 202 participants.

## Technical summary

Registry record NCT07083765. Randomized; triple masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2028-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 202 participants (planned count; ClinicalTrials.gov record NCT07083765, source copy `cardio:ctgov-nct07083765-2026-08-20`, retrieved 2026-10-26)
- Planned start: 2026-10 (anticipated) (ClinicalTrials.gov record NCT07083765, source copy `cardio:ctgov-nct07083765-2026-08-20`, retrieved 2026-10-26)
- Primary completion: 2028-05 (anticipated) (ClinicalTrials.gov record NCT07083765, source copy `cardio:ctgov-nct07083765-2026-08-20`, retrieved 2026-10-26)
- Completion: 2029-02 (anticipated) (ClinicalTrials.gov record NCT07083765, source copy `cardio:ctgov-nct07083765-2026-08-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07083765, source copy `cardio:ctgov-nct07083765-2026-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07083765-2026-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
- Acronym: RADAR
- Condition: Hypertension
- Condition: Hypertension,Essential
- Intervention (Drug): Dehydrated Alcohol Injection, USP
- Intervention (Procedure): Sham procedure
- Lead sponsor: Ablative Solutions, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Ablative Solutions, Inc. (`cardio:org-ablative-solutions-inc`)

## Provenance

Content hash: 4abd69015b40d4e2809af227ce56e6b60f4716a36d71790d69bcdb47724028f5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
